Hereditary Testing Market, By Test Type (Predictive Testing, Diagnostic Testing, Carrier Testing, Prenatal Testing, Newborn Screening, Preimplantation Genetic Diagnosis (PGD), and Pharmacogenomic Testing), By Technology (Next-Generation Sequencing (NGS),

The Global Hereditary Testing Market is estimated to be valued at USD 7.81 Bn in 2025 and is expected to reach USD 13.84 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.5% from 2025 to 2032.The global hereditary testing market has witnessed significant growth in recent years, driven by advancements in genetic technology and increasing awareness about the importance of early disease detection and prevention. Hereditary testing involves analyzing an individual's DNA to identify genetic variations that may increase the risk of developing certain inherited disorders. This market encompasses a wide range of genetic tests, including those for cancer, cardiovascular diseases, neurological disorders, and rare genetic conditions. As the understanding of the genetic basis of diseases continues to expand, the demand for hereditary testing is expected to rise, fueling market growth. Moreover, the increasing availability of direct-to-consumer genetic testing kits and the growing adoption of personalized medicine approaches are further contributing to the market's expansion.

Market Dynamics

The global hereditary testing market is influenced by several key drivers, restraints, and opportunities. One of the primary drivers is the increasing prevalence of genetic disorders worldwide, coupled with the rising awareness about the importance of early detection and prevention. Advancements in genetic sequencing technologies, such as next-generation sequencing (NGS), have made genetic testing more accessible and affordable, further driving market growth. Moreover, the growing adoption of personalized medicine approaches, which rely on genetic information to tailor treatment plans, is creating significant opportunities for the hereditary testing market. However, the market also faces certain restraints, such as the high cost of genetic testing, limited reimbursement policies, and ethical concerns surrounding genetic privacy and discrimination.

Key features of the study

• This report provides in-depth analysis of the global hereditary testing market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global hereditary testing market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Illumina, Inc., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Agilent Technologies, Inc., Fulgent Genetics, Inc., Genomic Health, Inc., Invitae Corporation, Roche Diagnostics, Siemens Healthineers, BGI Genomics, Quest Diagnostics, PerkinElmer, Inc., Eurofins Scientific, ArcherDX, and Color Genomics.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global hereditary testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary testing market

Market Segmentation

• Test Type Insights (Revenue, USD Bn, 2020 - 2032)
• Predictive Testing
• Diagnostic Testing
• Carrier Testing
• Prenatal Testing
• Newborn Screening
• Preimplantation Genetic Diagnosis (PGD)
• Pharmacogenomic Testing
• Technology Insights (Revenue, USD Bn, 2020 - 2032)
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Microarray
• Fluorescence In Situ Hybridization (FISH)
• Sanger Sequencing
• Array Comparative Genomic Hybridization (aCGH)
• Application Insights (Revenue, USD Bn, 2020 - 2032)
• Oncology
• Cardiovascular Diseases
• Neurology
• Metabolic Disorders
• Rare Diseases
• Reproductive Health
• Others
• Patient Age Group Insights (Revenue, USD Bn, 2020 - 2032)
• Pediatric
• Adult
• Geriatric
• End User Insights (Revenue, USD Bn, 2020 - 2032)
• Hospitals
• Specialty Clinics
• Diagnostic Laboratories
• Research Institutions
• Home Care Settings
• Others
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Myriad Genetics, Inc.
• Agilent Technologies, Inc.
• Fulgent Genetics, Inc.
• Genomic Health, Inc.
• Invitae Corporation
• Roche Diagnostics
• Siemens Healthineers
• BGI Genomics
• Quest Diagnostics
• PerkinElmer, Inc.
• Eurofins Scientific
• ArcherDX
• Color Genomics

Show more